On January 27, 2026, Inovio Pharmaceuticals, Inc. (the "Company") amended each of its outstanding Series A warrants issued on July 7, 2025 (the "Series A Warrants") to extend the expiration date of each outstanding Series A Warrant to 5:00 p.m. New York City time on March 31, 2026 (the "Amendment").

The Series A Warrants were issued in the Company's July 2025 underwritten public offering. The outstanding Series A Warrants are exercisable for up to 13,564,268 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") (or pre-fundedwarrants, each representing the right to purchase one share of Common Stock at an exercise price of $0.001 (the "Pre-FundedWarrants") in lieu thereof), and have an exercise price of $1.75 per share (or $1.749 per Pre-Funded Warrant)and would otherwise have expired at 5:00 p.m. New York City time on January 28, 2026, which is 30 days following the Company's public announcement of the acceptance of a Biologic License Application for INO-3107 bythe U.S. Food and Drug Administration. All other terms of the Series A Warrants remain unchanged.

A prospectus supplement amendment relating to the Amendment will be filed with the Securities and Exchange Commission.

The foregoing summary of the Amendment is qualified in its entirety by reference to the complete text of the Amendment, the form of which is filed as Exhibit 4.1 to this Current Report on Form 8-Kand is incorporated herein by reference.

The information contained in Item 1.01 of this Current Report on Form 8-Kis incorporated by reference into this Item 3.03.